Teva- Pharmaceutical Industries (TEVA) Stock News
$TEVA · NYSE · 1 stories in 30 daysBORSA has published 1 story on Teva- Pharmaceutical Industries (TEVA) in the past 30 days, 1 of it high impact. BORSA’s news read on TEVA is bullish at 81/100, based on 1 company event over the past 7 days. Teva- Pharmaceutical Industries’ next earnings report is scheduled for Tuesday, Nov 3 before the open.
The wire on $TEVA
newest first · updated · direct subject stories onlyduvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement in UC and Crohn's at Week 44 in the Phase 2b LTE study. Dose response observed. Safety consistent with induction. Biomarker data also presented.
bullish 85 · impact 70The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Teva- Pharmaceutical Industries (TEVA) stock: common questions
What is the latest Teva- Pharmaceutical Industries stock news?
The highest-impact TEVA story BORSA published in the past 30 days:
·